Managing the Cost of C. Difficile Infection: Are You Spending More Than You Know?
Jointly provided by
Medical Education Resources   

This activity is supported by an independent educational grant from Merck & Co. Inc.

You Are Invited to a CME/CE Live Webcast

Managing the Cost of C. Difficile Infection: Are You Spending More Than You Know?

Live Webcast Date

Thursday, January 14, 2021 1:00-2:30pm ET Click here to register

  • Increasing impact of C. Difficile Infection (CDI)
  • Latest guidelines, updates and management strategies for novel treatment options
  • Best practices in benefit design to control the costs of CDI
James T. Kenney, RPh, MBA
Founder and President
JT Kenney, LLC
Edmund Pezalla, MD, MPH
Enlightenment Bioconsult, LLC
A. Krishna Rao, MD, MS
Assistant Professor
Division of Infectious Diseases
Department of Internal Medicine
University of Michigan Medical School
  • This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.

The incidence of Clostridioides difficile infection or CDI, has increased over the past 2 decades. CDI differs from most other infections because it generally occurs after treatment with antimicrobial therapy. Some of the most commonly associated agents that CDI is associated with include clindamycin, ampicillin, cephalosporins, and fluoroquinolones. It is estimated that CDI costs the U.S. health care system $6 billion every year and average costs per case are more than $20,000.

A CDI expert will review treatment options and engage in peer-to-peer dialogue regarding recent developments and therapeutic recommendations. In addition, the faculty panel, including managed care experts, will review guideline-based recommendations to elucidate avoidable costs related to the management of CDI that may impact benefit design and coverage decision-making. Real-world case scenarios will be used to illustrate managed care best practices to evaluate all facets of medical and pharmacy management with initial and recurrent CDI, including assessment of existing and emerging therapies, and appropriate care management strategies to improve overall clinical and economic outcomes.


At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Describe recent insights into the safety, efficacy, and unique attributes of recently approved and emerging hemophilia treatment options.
  • Review the epidemiology and prevalence of C. Difficile Infection (CDI)
  • Evaluate novel treatment options for primary and recurrent CDI
  • Apply guideline-based management strategies for CDI
  • Illustrate avoidable costs related to CDI treatment management that can impact benefit design and coverage decision-making
Pre-Activity Learning Assessment and Opening Comments/Overview
James T. Kenney, RPh, MBA
CDI Clinical Update – Why the Increase?
A. Krishna Rao, MD, MS
Care Management Strategies to Address the Rising Costs of CDI
Edmund Pezalla, MD, MPH
CDI Case Scenarios and Best Practice Recommendations
James T. Kenney, RPh, MBA
Audience Q&A Session
Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation

Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 1.5 contact hours of continuing nursing education.
Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 1.5 contact hours.

Pharmacy Credit
Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: 0816-9999-20-169-L01-P
This activity is certified as knowledge-based CPE.

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

If you have any questions, please call (215) 619-8812 or email